A new therapeutic antibody masks ErbB2 to its partners
- PMID: 15093533
- DOI: 10.1016/s1535-6108(04)00088-1
A new therapeutic antibody masks ErbB2 to its partners
Abstract
In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2 with the other ErbB receptors. Pertuzumab's novel mode of action might offer additional therapeutic opportunities for treatment of tumors expressing ligand-activated ErbB2.
Comment on
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.Cancer Cell. 2004 Apr;5(4):317-28. doi: 10.1016/s1535-6108(04)00083-2. Cancer Cell. 2004. PMID: 15093539
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous